Zydus receives USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets

Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Extended—Release Tablets, (US RLD — JANUMET XR), 50 mg/500 mg, 50 mg/ 1,000 mg and 100 mg/ 1,000 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

It contains two oral antidiabetic medications used in the management of type 2 diabetes – Sitagliptin and metformin hydrochloride extended—release.

The group now has 255 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Notify of